Pharmaceutical and services company Clinigen Group’s Clinical Services has expanded its ‘on-demand’ supply service with Accord Healthcare into France.
This arrangement will allow the customers of Clinical Services to continue to have access to the Accord portfolio, both UK and EU packs of product, for their clinical trials across the world.
The CS team will solely take up all on-demand clinical trial supply enquiries, enabling Clinigen to provide a secure, fast and flexible supply chain for the distribution of Accord’s European product portfolio.
Accord’s European product portfolio is distributed among contract research organisations (CROs), pharmaceutical manufacturers, clinical trial contract packagers and other specialist service providers.
Furthermore, customers will be able to gain quick access to important products from Accord’s generic oncology Injectable Product and solid dose product portfolio.
Clinigen group CEO Shaun Chilton said: “Expanding our ‘on-demand’ supply operations in Europe builds on our strong partnership with Accord. Having service operations in both the UK and in France enables us to service clients more efficiently across geographies. We know from experience that clients appreciate our ability to supply and distribute medicines across borders on an ‘on demand’ basis, in a timely manner. Being able to supply both UK and European packs of Accord products provides even more flexibility to our clients running their clinical trials on a global basis.
“The span of the Accord partnership across two of our divisions is a good demonstration of the Clinigen business model and the synergies between divisions. It demonstrates how Clinigen can meet the needs of both pharma clients and healthcare professional customers on a global basis.”
Accord Healthcare commercial senior vice president Phill Semmens said: “We have a strong partnership in place with Clinigen which continues to go from strength to strength. When we first established the ‘on demand’ service, it was the first of its kind for the pharma industry.
“By expanding its UK operations into France, Clinigen can ensure our products are even more accessible for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials. We look forward to continuing our work with the Clinigen team to serve our goal of benefitting treatment options for patients and broadening medical knowledge.”
Since 2012, Clinigen’s CS business and Accord have been partners in the delivery of oncology Injectable Products.
In 2019, the partnership was extended to cover Accord’s European Solid Dose Products, and to set up an ‘on-demand’ supply service.
The ‘on-demand’ supply service will now be operational in France as well as the UK.
Earlier this year, Clinigen’s Global Access business also prolonged its partnership with Accord for five more years.
In the event of a supply chain disruption or drug shortage, through unlicensed access to Accord’s extensive portfolio, Clinigen will be able to provide its service to health care professionals and their patients across the world.